(VRTX) Vertex Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92532F1003

Cystic Fibrosis, Gene Therapy, Sickle Cell, Thalassemia, Pain Relief

Biotechnology
Market Cap in USD: 118,929m

IPO / Inception: 1991-07-24
12m vs SPY: -12.4%

EPS (Earnings per Share)

EPS CAGR: -6.10%
EPS Trend: -18.7%

Last SUE: -0.91
Qual. Beats: 0

Revenue

Rev. CAGR: 11.11%
Rev. Trend: 98.5%

Last SUE: 0.23
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	25.4%
Value at Risk 5%th	39.6%
Relative Tail Risk	-5.03%

Reward TTM
Sharpe Ratio	0.32
Alpha	-2.24
CAGR/Max DD	0.47

Character TTM
Hurst Exponent	0.229
Beta	0.429
Beta Downside	0.147

Drawdowns 3y
Max DD	29.07%
Mean DD	7.99%
Median DD	6.46%

Description: VRTX Vertex Pharmaceuticals December 02, 2025

Vertex Pharmaceuticals (NASDAQ:VRTX) is a U.S. biotech focused on cystic fibrosis (CF), commercializing a suite of CFTR modulators-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO-that together address >90 % of the CF genotype spectrum and generate the bulk of the company’s revenue (≈ $7 billion FY 2023). The firm also pursues non-CF indications such as sickle-cell disease (CASGEVY), acute pain (JOURNAVX), and gene-editing platforms through collaborations with CRISPR Therapeutics, Moderna, and Entrada Therapeutics.

Key pipeline milestones include VX-522 (CFTR-mRNA therapy, Phase 1/2), inaxaplin (APOL1-mediated kidney disease, Phase 2), and early-stage programs for type 1 diabetes (VX-880, VX-264) and myotonic dystrophy (VX-670). As of Q4 2024, Vertex’s R&D spend was ≈ $2.1 billion, reflecting a ≈ 30 % increase YoY, while its cash runway exceeds $10 billion, providing flexibility to advance these high-risk assets.

Sector-wide drivers-rising prevalence of rare-disease diagnoses, expanding payer willingness to fund high-value gene-editing therapies, and a ~ 12 % CAGR in the global CF market-support Vertex’s growth outlook, but pricing scrutiny and competitive gene-therapy entrants remain material risks. For a deeper, data-rich view of how Vertex’s valuation stacks up against these dynamics, a quick look at ValueRay’s analyst toolkit can be useful.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (3.68b TTM) > 0 and > 6% of Revenue (6% = 703.4m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA 19.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 51.98% (prev 54.89%; Δ -2.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 3.72b > Net Income 3.68b (YES >=105%, WARN >=100%)

Net Debt (-3.10b) to EBITDA (4.66b) ratio: -0.67 <= 3.0 (WARN <= 3.5)

Current Ratio 2.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (257.6m) change vs 12m ago -1.30% (target <= -2.0% for YES)

Gross Margin 86.28% (prev 86.11%; Δ 0.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.78% (prev 47.76%; Δ 2.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 348.4 (EBITDA TTM 4.66b / Interest Expense TTM 12.8m) >= 6 (WARN >= 3)

Altman Z'' 6.22

(A) 0.25 = (Total Current Assets 10.57b - Total Current Liabilities 4.48b) / Total Assets 24.86b

(B) 0.50 = Retained Earnings (Balance) 12.37b / Total Assets 24.86b

(D) 1.63 = Book Value of Equity 12.31b / Total Liabilities 7.54b

Total Rating: 6.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.34

1. Piotroski 7.0pt

2. FCF Yield 2.92%

3. FCF Margin 28.47%

4. Debt/Equity 0.11

5. Debt/Ebitda -0.67

6. ROIC - WACC (= 14.68)%

7. RoE 21.81%

8. Rev. Trend 98.48%

9. EPS Trend -18.70%

What is the price of VRTX shares?

As of January 17, 2026, the stock is trading at USD 449.53 with a total of 1,295,451 shares traded.
Over the past week, the price has changed by -6.55%, over one month by -3.68%, over three months by +7.60% and over the past year by +3.46%.

Is VRTX a buy, sell or hold?

Vertex Pharmaceuticals has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy VRTX.

Strong Buy: 14
Buy: 4
Hold: 14
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the VRTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	500.4	11.3%
Analysts Target Price	500.4	11.3%
ValueRay Target Price	492.4	9.5%

VRTX Fundamental Data Overview January 11, 2026

P/E Trailing = 32.6892
P/E Forward = 24.6305
P/S = 10.1447
P/B = 6.8808
P/EG = 0.5801
Revenue TTM = 11.72b USD
EBIT TTM = 4.46b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 1.83b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 92.3m USD (from shortTermDebt, last fiscal year)
Debt = 1.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.10b USD (from netDebt column, last quarter)
Enterprise Value = 114.48b USD (118.93b + Debt 1.83b - CCE 6.29b)
Interest Coverage Ratio = 348.4 (Ebit TTM 4.46b / Interest Expense TTM 12.8m)
EV/FCF = 34.30x (Enterprise Value 114.48b / FCF TTM 3.34b)
FCF Yield = 2.92% (FCF TTM 3.34b / Enterprise Value 114.48b)
FCF Margin = 28.47% (FCF TTM 3.34b / Revenue TTM 11.72b)
Net Margin = 31.35% (Net Income TTM 3.68b / Revenue TTM 11.72b)
Gross Margin = 86.28% ((Revenue TTM 11.72b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 86.52% (prev 86.25%)
Tobins Q-Ratio = 4.60 (Enterprise Value 114.48b / Total Assets 24.86b)
Interest Expense / Debt = 0.18% (Interest Expense 3.30m / Debt 1.83b)
Taxrate = 16.62% (215.9m / 1.30b)
NOPAT = 3.72b (EBIT 4.46b * (1 - 16.62%))
Current Ratio = 2.36 (Total Current Assets 10.57b / Total Current Liabilities 4.48b)
Debt / Equity = 0.11 (Debt 1.83b / totalStockholderEquity, last quarter 17.32b)
Debt / EBITDA = -0.67 (Net Debt -3.10b / EBITDA 4.66b)
Debt / FCF = -0.93 (Net Debt -3.10b / FCF TTM 3.34b)
Total Stockholder Equity = 16.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.60% (Net Income 3.68b / Total Assets 24.86b)
RoE = 21.81% (Net Income TTM 3.68b / Total Stockholder Equity 16.85b)
RoCE = 23.87% (EBIT 4.46b / Capital Employed (Equity 16.85b + L.T.Debt 1.83b))
RoIC = 22.07% (NOPAT 3.72b / Invested Capital 16.85b)
WACC = 7.39% (E(118.93b)/V(120.76b) * Re(7.50%) + D(1.83b)/V(120.76b) * Rd(0.18%) * (1-Tc(0.17)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.19%
[DCF Debug] Terminal Value 73.11% ; FCFF base≈3.34b ; Y1≈2.19b ; Y5≈999.5m
Fair Price DCF = 98.74 (EV 21.95b - Net Debt -3.10b = Equity 25.05b / Shares 253.7m; r=7.39% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -18.70 | EPS CAGR: -6.10% | SUE: -0.91 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 11.11% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.82 | Chg30d=-0.012 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=20.24 | Chg30d=-0.006 | Revisions Net=+1 | Growth EPS=+9.7% | Growth Revenue=+8.7%

Additional Sources for VRTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle